Importance: Postoperative urinary retention (POUR) is a frequent and burdensome complication following urogynecologic surgery. Studies in other specialties suggest intraoperative glycopyrrolate may increase POUR risk; however, this association has not been explored in prolapse surgery, where baseline rates of POUR are higher and same-day surgery is now standard.
Objective: The objective of this study was to evaluate the association between intraoperative glycopyrrolate and POUR among patients undergoing laparoscopic prolapse repair with same-day discharge.
Study design: We conducted a retrospective cohort study of patients undergoing outpatient laparoscopic sacrocolpopexy, sacrocervicopexy, or sacrohysteropexy surgery from June 2017 through January 2024. All patients underwent a standardized postoperative voiding trial with 300 mL of saline instilled through a transurethral catheter, followed by a void within 15 minutes. The exposure was intraoperative glycopyrrolate; the primary outcome was POUR, defined as voiding <200 mL. Log-binomial regression was used to estimate relative risk (RR) and 95% CI, adjusting for age, body mass index, surgeon, concomitant sling, and perioperative scopolamine use.
Results: Among 321 patients, 77% received glycopyrrolate. After adjusting for confounders, patients who received glycopyrrolate had an increased risk of POUR (RR: 1.93, 95% CI; 1.16 to 3.22) compared with those who did not receive glycopyrrolate. This relationship may be dose-dependent: patients who received a low dose had an RR of 1.28 (95% CI; 0.70 to 2.33), while those receiving a high dose had an RR of 2.57 (95% CI; 1.51 to 4.38).
Conclusions: Intraoperative glycopyrrolate was associated with a significantly increased POUR risk, particularly at higher doses commonly used during neuromuscular blockade reversal. Surgeons should engage with anesthesiologists to discuss the potential effect of drugs on postoperative outcomes.
扫码关注我们
求助内容:
应助结果提醒方式:
